{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:27:20Z","timestamp":1787135240382,"version":"build-2736575974"},"reference-count":26,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infect. Dis. Rep.","Infectious Disease Reports"],"abstract":"<jats:p>Background\/Objectives: Clostridioides difficile infection (CDI) is associated with substantial morbidity and high recurrence rates. Current guidelines recommend fidaxomicin over oral vancomycin due to reduced recurrence; however, its high acquisition cost limits widespread adoption. Our health system implemented criteria restricting fidaxomicin to patients with the highest risk for recurrence. This study evaluated the impact of this strategy on CDI recurrence and antimicrobial expenditures. Methods: We conducted a multicenter, retrospective matched cohort study across a rural health system from January 2023 through March 2026. The fidaxomicin criteria for use (intervention) went into effect on 1 January 2025. Adult hospitalized patients with an initial CDI episode treated with oral vancomycin and\/or fidaxomicin were included. Patients with severe CDI or prior CDI episodes were excluded. A 2:1 matching algorithm based on key recurrence risk factors was used to compare pre-implementation (before criteria for use) and post-implementation (after criteria for use) cohorts. The primary outcomes were 28-day and 90-day CDI recurrences. Secondary outcomes included antimicrobial utilization and annualized expenditures. Results: A total of 144 matched patients were analyzed (96 control and 48 intervention). Fidaxomicin use decreased from 40.6% to 8.3% following implementation (p &lt; 0.001). Annualized fidaxomicin expenditures declined by 54.7%. CDI recurrence rates were similar between groups: 28-day recurrence was 5.2% in the control group versus 6.2% in the intervention group, and 90-day recurrence was 7.3% versus 10.4%, respectively, with statistical non-inferiority at 28 days (p = 0.014). Conclusions: Implementation of risk-based fidaxomicin use criteria significantly reduced utilization and costs without a statistically significant increase in CDI recurrence. These findings support a targeted stewardship approach to optimize resource use while maintaining comparable clinical outcomes.<\/jats:p>","DOI":"10.3390\/idr18040090","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:30:53Z","timestamp":1787131853000},"page":"90","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Hospital-Based Fidaxomicin Use Criteria on Clostridioides difficile Recurrence: A Retrospective Matched Cohort Study"],"prefix":"10.3390","volume":"18","author":[{"given":"Song","family":"Kwon","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Marshfield Clinic Region\u2013Sanford Health, Marshfield, WI 54449, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-5689","authenticated-orcid":false,"given":"Rachel","family":"Gabor","sequence":"additional","affiliation":[{"name":"Biostatistics, Marshfield Clinic Health System and Marshfield Clinic Research Institute, 1000 North Oak Avenue, Marshfield, WI 54449, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Whitfield","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Marshfield Clinic Region\u2013Sanford Health, Marshfield, WI 54449, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes","volume":"382","author":"Guh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5009\/gnl18071","article-title":"Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention","volume":"13","author":"Song","year":"2019","journal-title":"Gut Liver"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1093\/cid\/cis357","article-title":"Relapse versus reinfection: Recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin","volume":"55","author":"Figueroa","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1469-0691.12046","article-title":"Can we identify patients at high risk of recurrent Clostridium difficile infection?","volume":"18","author":"Kelly","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1017\/ice.2014.88","article-title":"Risk factors for recurrent Clostridium difficile infection: A systematic review and meta-analysis","volume":"36","author":"Deshpande","year":"2015","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Abou Chakra, C.N., Pepin, J., Sirard, S., and Valiquette, L. (2014). Risk factors for recurrence, complications and mortality in Clostridium difficile infection: A systematic review. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098400"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jinf.2009.03.010","article-title":"Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes","volume":"58","author":"Johnson","year":"2009","journal-title":"J. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jhin.2008.08.012","article-title":"Meta-analysis to assess risk factors for recurrent Clostridium difficile infection","volume":"70","author":"Garey","year":"2008","journal-title":"J. Hosp. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/cid\/cir404","article-title":"Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections","volume":"53","author":"Mullane","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1093\/cid\/cis338","article-title":"Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI","volume":"55","author":"Louie","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1093\/cid\/cis453","article-title":"Fidaxomicin inhibits spore production in Clostridium difficile","volume":"55","author":"Babakhani","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40121-021-00480-0","article-title":"Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States","volume":"11","author":"Jiang","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_14","unstructured":"R Core Team (2025). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: https:\/\/www.R-project.org\/."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Caldwell, A.R. (2022). Exploring Equivalence Testing with the Updated TOSTER R Package. PsyArXiv Prepr. Serv., 1\u201328.","DOI":"10.31234\/osf.io\/ty8de"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/1948550617697177","article-title":"Equivalence tests: A practical primer for t-tests, correlations, and meta-analyses","volume":"8","author":"Lakens","year":"2011","journal-title":"Soc. Psychol. Pers. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: Nonparametric Preprocessing for Parametric Causal Inference","volume":"42","author":"Ho","year":"2011","journal-title":"J. Stat. Softw."},{"key":"ref_18","unstructured":"Griefer, N. (2026, July 02). Cobalt: Covariate Balance Tables and Plots. Available online: https:\/\/cran.r-project.org\/web\/packages\/cobalt\/index.html."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"ofac492.470","DOI":"10.1093\/ofid\/ofac492.470","article-title":"Guideline adaptation of fidaxomicin as first-line therapy for Clostridioides difficile infection in institutions across the United States","volume":"9","author":"Basir","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_20","unstructured":"(2026, July 02). VA Formulary Advisor, Available online: https:\/\/www.va.gov\/formularyadvisor\/drugs\/4030775-FIDAXOMICIN-TAB."},{"key":"ref_21","unstructured":"(2026, July 02). Carolina Antimicrobial Stewardship Program (CASP) Resources. Available online: https:\/\/www.med.unc.edu\/casp\/clinical-guidelines\/."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1017\/ice.2021.456","article-title":"Evaluation of fidaxomicin use in community hospitals after a clinical guideline change at a large health system and opportunities for stewardship","volume":"44","author":"Khadem","year":"2023","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1200\/OP.20.00312","article-title":"Changes in Intravenous Immunoglobulin Usage for Hypogammaglobulinemia After Implementation of a Stewardship Program","volume":"17","author":"Derman","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jhin.2026.05.039","article-title":"Educational intervention to optimize antibiotic prescribing: A narrative review of recent evidence","volume":"174","author":"Acampora","year":"2026","journal-title":"J. Hosp. Infect."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"dlae192","DOI":"10.1093\/jacamr\/dlae192","article-title":"Effectiveness of work-based educational interventions for antimicrobial stewardship: A systematic review","volume":"6","author":"Langdridge","year":"2024","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/cid\/ciae604","article-title":"Audit and feedback interventions for antibiotic prescribing in primary care: A systematic review and meta-analysis","volume":"80","author":"Xu","year":"2025","journal-title":"Clin. Infect. Dis."}],"container-title":["Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7449\/18\/4\/90\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:57:13Z","timestamp":1787133433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7449\/18\/4\/90"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["idr18040090"],"URL":"https:\/\/doi.org\/10.3390\/idr18040090","relation":{},"ISSN":["2036-7449"],"issn-type":[{"value":"2036-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}